Author: admin

“Phototherapy for Psoriasis Treatment Market”

(Albnay, USA) DelveInsight’s Phototherapy for Psoriasis Market Insights report proffers a detailed comprehension of the Phototherapy for Psoriasis market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Phototherapy for Psoriasis market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan).

The Phototherapy for Psoriasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Phototherapy for Psoriasis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Phototherapy for Psoriasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Phototherapy for Psoriasis market.

Request for sample report @ Phototherapy for Psoriasis Market Outlook

Some of the salient features from the Phototherapy for Psoriasis Market Report:

• Phototherapy for Psoriasis market is expected to grow at a decent CAGR by 2032.
• DelveInsight analysts suggested that the Phototherapy for Psoriasis market size is expected to increase drastically owing to the launches of several potential emerging therapies during the study period.
• Key pharmaceutical Phototherapy for Psoriasis companies such as Phothera, Bristol Myers Squibb, Zerigo Health, Solarc Systems Inc, Dermalux and others are reported to bring a significant shift in the Phototherapy for Psoriasis.
• In 2022, the total diagnosed prevalent cases of psoriasis in the US were ~8 million, projected to increase during the forecast period (2023–2032).
• In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
• In September 2022, Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1,2Sotyktu is not recommended for use in combination with other potent immunosuppressants.

For further information on the market impact by therapies, download the Phototherapy for Psoriasis sample @ Phototherapy for Psoriasis Therapeutic Scenario

Phototherapy for Psoriasis Overview

Phototherapy is a widely used treatment for psoriasis, leveraging controlled exposure to ultraviolet (UV) light to reduce inflammation and slow the excessive growth of skin cells. The primary types of phototherapy include narrowband UVB (NB-UVB), broadband UVB, psoralen plus UVA (PUVA), and targeted laser treatments such as the excimer laser. These therapies are particularly beneficial for moderate to severe psoriasis cases that do not respond well to topical treatments.

The demand for phototherapies is driven by their cost-effectiveness, non-invasive nature, and efficacy in managing psoriasis symptoms. Advancements in technology have led to the development of home-based phototherapy devices, improving accessibility for patients. Additionally, increased awareness and favorable reimbursement policies in some regions have further boosted market adoption.

However, market growth is hindered by safety concerns associated with long-term UV exposure, which increases the risk of skin cancer. The availability of biologic and systemic treatments, which offer targeted mechanisms with fewer side effects, also poses competition. Furthermore, high equipment costs and limited access to treatment centers, especially in developing regions, remain significant challenges.

Despite these barriers, the phototherapy market is expected to grow due to ongoing research and technological advancements, ensuring safer and more efficient treatment options for psoriasis patients.

Phototherapy for Psoriasis Epidemiology Segmentation

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Psoriasis Epidemiology Segmentation:

The Psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Diagnosed Prevalence of Psoriasis in Adults
• Diagnosed Prevalence of Psoriasis in Paediatrics
• Diagnosed Prevalence of Psoriasis by Types
• Diagnosed Prevalence of Psoriasis by Location
• Diagnosed Prevalence of Psoriasis by Severity

Keen to learn how Phototherapy for Psoriasis Epidemiological Trends are going to appear in 2032 for the 7MM, Download @ Phototherapy for Psoriasis Prevalence

Phototherapy for Psoriasis Market Outlook

The Phototherapies for Psoriasis Market is driven by several key factors, primarily the increasing global prevalence of psoriasis, which is fueling demand for effective treatment options like phototherapy. Technological advancements, including excimer laser therapy and targeted UVB treatments, have enhanced efficacy and patient convenience, further promoting market expansion. Additionally, rising awareness and improved diagnostic rates have led to higher patient adoption of phototherapy. Favorable reimbursement policies in some regions are improving accessibility, while the cost-effectiveness and minimally invasive nature of phototherapy make it an attractive alternative to biologics and systemic treatments. Moreover, the rising demand for home-based phototherapy devices is expanding market penetration, particularly in areas with limited healthcare access. However, several barriers hinder market growth, including safety concerns related to long-term UV exposure, which increases the risk of skin cancer. The availability of alternative treatments, such as biologics and systemic therapies with higher efficacy, poses significant competition. Furthermore, the high initial cost of phototherapy equipment, restricted access to specialized treatment centers in rural areas, and stringent regulatory requirements for device approval limit widespread adoption. Despite these challenges, continuous research and development efforts are expected to drive innovation and improve the safety and effectiveness of phototherapy solutions for psoriasis management.

Discover more about therapy set to grab substantial Phototherapy for Psoriasis market share @ Phototherapy for Psoriasis Treatment Market

Scope of the Phototherapy for Psoriasis Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Phototherapy for Psoriasis Companies: Phothera, Bristol Myers Squibb, Zerigo Health, Solarc Systems Inc, Dermalux and others
• Phototherapy for Psoriasis Therapeutic Assessment: Phototherapy for Psoriasis current marketed and emerging therapies
• Phototherapy for Psoriasis Dynamics: Phototherapy for Psoriasis drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Phototherapy for Psoriasis Access and Reimbursement

Request for sample report @ https://www.delveinsight.com/sample-request/phototherapies-for-psoriasis-market

Table of Contents

1. Key Insights

2. Report Introduction

3. Phototherapy for Psoriasis Market Overview at a Glance

4. Executive Summary of Phototherapy for Psoriasis

5. Phototherapy for Psoriasis Epidemiology and Market Methodology

6. Phototherapy for Psoriasis: Disease Background and Overview

7. Diagnosis of Phototherapy for Psoriasis

8. Phototherapy for Psoriasis Treatment

9. Conclusion for Phototherapy for Psoriasis

10. Phototherapy for Psoriasis Epidemiology and Patient Population

11. Phototherapy for Psoriasis Patient Journey

12. Key Endpoints in Phototherapy for Psoriasis Clinical Trials

13. Phototherapy for Psoriasis Marketed Therapies

14. Phototherapy for Psoriasis Emerging Therapies

15. Phototherapy for Psoriasis: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Phototherapy for Psoriasis Market Drivers

19. Phototherapy for Psoriasis Market Barriers

20. Phototherapy for Psoriasis SWOT Analysis

21. Phototherapy for Psoriasis Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Phototherapy for Psoriasis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

“Pressure Ulcer Treatment Market”

(Albany, USA) DelveInsight’s ” Pressure Ulcer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Pressure Ulcer, historical and forecasted epidemiology as well as the Pressure Ulcer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

To strategically aid Pressure Ulcer companies developing drugs for Pressure Ulcer, DelveInsight launched a report titled as “Pressure Ulcer Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Pressure Ulcer market.

Get a free sample of “Pressure Ulcer Market Report”

Pressure Ulcer Market Report’s Key Highlights:

• Pressure Ulcer market is expected to grow at a decent CAduring the study period in 7MM.
• Key Pressure Ulcer Companies: Phagelux, MiMedx, EyeGene, Shionogi, NovaLead Pharma, Smith & Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, Coloplast Group, and others.
• Promising pressure ulcer therapies are SR-0379, EGT 022, GM-XANTHO, others.
• The incidence of Pressure Ulcers is more in patients who are previously suffering from Diabetes.
• The prevalence of diabetes in the 7MM was estimated to be 537 million cases in adults, out of which around 150 million suffer from ulcers at some point.
• According to the studies it is estimated that in the United States 10% of the people experience Ulcers at some point in their lifetime.
• The Pressure Ulcermarket is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various Pressure Ulcer pipeline products will significantly revolutionize the Pressure Ulcer market dynamics
• In October 2024, Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing to integrate lidocaine for the management of painful skin wounds. Microlyte® Ag/Lidocaine utilizes Imbed’s patented synthetic matrix to deliver ionic and metallic silver alongside lidocaine, providing both antimicrobial protection and local anesthetic effects. The dressing releases 40mg of lidocaine hydrochloride USP per 100cm² of wound surface area, equivalent to a 4% w/w gel. The advanced Microlyte® Ag/Lidocaine wound dressing is indicated for the management of a variety of partial- and full-thickness wounds under the supervision of a healthcare professional, including venous stasis ulcers, pressure sores, ischemic ulcers, partial thickness burns, donor site wounds, surgical wounds, post-surgical incisions, abrasions and lacerations.
• In July 2024, Xantho Biotechnology has announced results of a Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO in Pressure Ulcer Patients

Pressure Ulcer Country based Treatment Analysis:

The Pressure Ulcer treatment market report provides treatment regimen across the 7MM. It will help companies to analyse the practices followed across 7MM, patient journey and advances in Pressure Ulcer Therapies that have the potential to transform treatment paradigms and improve patient outcomes.

Pressure ulcers, also known as bedsores or pressure sores, are localized injuries to the skin and/or underlying tissue due to prolonged pressure on the skin. They commonly develop in individuals who are bedridden, use a wheelchair, or have limited mobility. These ulcers usually form over bony prominences, such as the heels, hips, tailbone, and elbows.

The development of pressure ulcers is influenced by various factors, including pressure intensity, duration, and the individual’s overall health. Reduced blood flow to the affected area leads to tissue damage, causing pain, open wounds, and sometimes severe complications like infections or tissue necrosis.

Preventing pressure ulcers involves regular repositioning, maintaining proper nutrition, using specialized support surfaces, and ensuring good skincare. Early detection and appropriate management are crucial to prevent their progression and promote healing. Healthcare professionals provide tailored treatments, including wound care, infection control, and pressure redistribution strategies, to manage pressure ulcers effectively.

Download the report to understand which factors are driving Pressure Ulcer epidemiology trends @ Pressure Ulcer Epidemiology Forecast

Pressure Ulcer Epidemiology Insights:

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Pressure Ulcer. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools. The epidemiology in report is segmented as:

Pressure Ulcer Epidemiology Segmentation:

• Total Prevalence of Pressure Ulcer
• Prevalent Cases of Pressure Ulcer by severity
• Gender-specific Prevalence of Pressure Ulcer
• Diagnosed Cases of Episodic and Chronic Pressure Ulcer

Pressure Ulcer Companies and Therapies:

EGT 022: EyeGene

EGT 022 is a RGD motif containing recombinant polypeptide from human-derived protein ADAM-15. It is being developed by EyeGene Inc.

And Many Others.

Emerging Pressure Ulcer drugs Uptake:

• In October 2024, Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing to integrate lidocaine for the management of painful skin wounds. Microlyte® Ag/Lidocaine utilizes Imbed’s patented synthetic matrix to deliver ionic and metallic silver alongside lidocaine, providing both antimicrobial protection and local anesthetic effects. The dressing releases 40mg of lidocaine hydrochloride USP per 100cm² of wound surface area, equivalent to a 4% w/w gel. The advanced Microlyte® Ag/Lidocaine wound dressing is indicated for the management of a variety of partial- and full-thickness wounds under the supervision of a healthcare professional, including venous stasis ulcers, pressure sores, ischemic ulcers, partial thickness burns, donor site wounds, surgical wounds, post-surgical incisions, abrasions and lacerations.
• In July 2024, Xantho Biotechnology has announced results of a Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO in Pressure Ulcer Patients
• In March 2021, Smith+Nephew announced the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped significantly reduce dressing change frequency and weekly dressing costs while improving treatment satisfaction for clinicians and patients in a community setting.
• In February 2021, Axis Biosolutions received European CE mark approval for the advanced wound care product, MAxiCel, which is used in several chronic wounds, including pressure ulcers.

To know more about Pressure Ulcer companies working in the treatment market, visit @ Pressure Ulcer Clinical Trials and Therapeutic Assessment

Pressure Ulcer Market Forecast:

• The research includes a thorough analysis of the past and projected markets for Pressure Ulcer, which includes pharmacological outreach in the 7MM nations.
• The dynamics of the Pressure ulcer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Thymosin Beta 4, Ibuprofen, and others during the forecasted period 2019-2032.
• Rising prevalence, increasing prevalence, less competition for upcoming therapies and Companies shifting their focus to this area, despite low awareness of the disease are fuelling the Pressure Ulcer Market.

Discover more about therapies set to grab major Pressure Ulcer market share @ Pressure Ulcer Treatment Market

Scope of the Pressure Ulcer Market Report:

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Key Companies: Phagelux, MiMedx, EyeGene, Shionogi, NovaLead Pharma, Smith & Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, Coloplast Group, and others.

Request for Sample Report @ https://www.delveinsight.com/sample-request/pressure-ulcers-market

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Pressure Ulcer market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the Pressure Ulcer market, including the competitive environment, key companies developing drugs for Pressure Ulcer, and their strategies. By analyzing Pressure Ulcer market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analysing Pressure Ulcer epidemiological trends, country wise patient journeys and existing treatment practices can helps in identifying gaps and opportunities within the Pressure Ulcer market. This involves recognizing areas where current Pressure Ulcer treatments may be insufficient or where there is an unmet need. The Pressure Ulcer market report is curated by taking account of various KOLs dealing with Pressure Ulcer. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific Pressure Ulcer market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the Pressure Ulcer market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading Pressure Ulcer companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Pressure Ulcer market with clarity and purpose.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pressure Ulcer Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

“Psoriasis Vulgaris Treatment Market”

(Albnay, USA) DelveInsight’s Psoriasis Vulgaris Market Insights report proffers a detailed comprehension of the Psoriasis Vulgaris market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Psoriasis Vulgaris market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan).

The Psoriasis Vulgaris market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Psoriasis Vulgaris market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Psoriasis Vulgaris treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Psoriasis Vulgaris market.

Request for sample report @ Psoriasis Vulgaris Market Outlook

Some of the salient features from the Psoriasis Vulgaris Market Report:

• Psoriasis Vulgaris is a vibrant type of umbrella indication of Psoriasis. As per DelveInsight’s assessment, the market for Psoriasis is supposed to advance upto USD 25,260 million by 2032.
• DelveInsight analysts suggested that the Psoriasis Vulgaris market size is expected to increase drastically owing to the launches of several potential emerging therapies during the study period.
• Key pharmaceutical Psoriasis Vulgaris companies such as Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma, and others are reported to bring a significant shift in the Psoriasis Vulgaris.
• The Psoriasis Vulgaris emerging therapies that are expected to launch in the forecast period include DMB-3115, Deucravacitinib, BAT2306, and others.
• As per DelveInsight’s analysis approximately 15 million people worldwide have psoriasis, including around 8 million people in the US and more than 6 million people in EU5. About 80% of those patients suffer from Psoriasis Vulgaris.
• Despite drug development advances in the past decade, patient survey data suggest that moderate-to-severe Psoriasis Vulgaris is being undertreated.

For further information on the market impact by therapies, download the Psoriasis Vulgaris sample @ Psoriasis Vulgaris Therapeutic Scenario

Psoriasis Vulgaris Overview

Psoriasis vulgaris, or plaque psoriasis, is a chronic autoimmune skin disorder characterized by red, scaly, and inflamed plaques that commonly appear on the scalp, elbows, knees, and lower back. It occurs when the immune system mistakenly triggers rapid skin cell turnover, causing an excessive buildup of skin cells.

The exact cause remains unknown, but genetics, immune dysfunction, and environmental factors play key roles. Psoriasis vulgaris Triggers include stress, infections, medications (e.g., beta-blockers, NSAIDs), smoking, alcohol, and cold weather.

Common Psoriasis vulgaris symptoms include itching, burning, and skin cracking, which can significantly impact quality of life. Some patients also develop psoriatic arthritis, causing joint pain and stiffness.

Psoriasis vulgaris Treatment options range from topical therapies (steroids, vitamin D analogs), phototherapy, systemic medications (methotrexate, cyclosporine), and biologic drugs targeting inflammatory pathways like TNF-α, IL-17, and IL-23 inhibitors.

While no cure exists, lifestyle modifications, such as moisturizing, stress management, and avoiding triggers, help manage symptoms. Early diagnosis and personalized treatment are crucial for minimizing flares and improving skin health.

For severe cases, biologics have revolutionized treatment, offering long-term control and better patient outcomes. Regular follow-ups with dermatologists and rheumatologists ensure effective disease management.

Psoriasis Vulgaris Epidemiology Segmentation

As per the assessment of DelveInsight, Psoriasis is the most common inflammatory disease in the United States, affecting as many as 8 million Americans and this number is expected to increase during the study period.

As per DelveInsight’s estimates, the total diagnosed prevalent cases of Psoriasis Vulgaris in the US are estimated to be more than 6 million in 2021, the highest among the 7MM and are predicted to increase during the study period (2019-2032).

It is observed that about 80-90% of people living with psoriasis experience Psoriasis Vulgaris and approximately 20% of people suffering from Psoriasis have moderate-to-severe Psoriasis Vulgaris.

The Psoriasis Vulgaris Market report offers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into

• Total Prevalent Cases of Psoriasis Vulgaris
• Gender-specific Prevalent Cases of Psoriasis Vulgaris
• Age-specific Cases of Psoriasis Vulgaris
• Severity-specific Prevalence of Psoriasis Vulgaris

Keen to learn how Psoriasis Vulgaris Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Psoriasis Vulgaris Prevalence

Psoriasis Vulgaris Market Outlook

Although Psoriasis Vulgaris cannot be permanently cured, therapeutic interventions for localized Psoriasis Vulgaris should begin with patient education and the use of topical corticosteroids with or without coal tar or calcipotriene. Thereafter, anthralin or tazarotene, alone or in combination with steroids, can be used following first-line treatment failure or subsequent loss of response to first-line therapy. Alternatively, if control is difficult to achieve or disease is widespread, phototherapy, with and without drugs such as psoralen or retinoids, may be required.

There are many FDA-approved Psoriasis Vulgaris treatment therapies available in the market. Some of these include Skyrizi produced by AbbVie which was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Ilumya is manufactured by Sun Pharma (also known by its generic name tildrakizumab-asmn), it was FDA approved in March 2018 for moderate-to-severe Psoriasis Vulgaris treatment in adults. Then, Johnson & Johnson’s Psoriasis Vulgaris treatment drug namely Tremfya (also known by its generic name guselkumab) was FDA approved in July 2017. Other FDA-approved and currently marketed Psoriasis Vulgaris treatment drugs include Cimzia by UCB, Inc., Taltz (ixekizumab) by Eli Lilly and Company, and Cosentyx (secukinumab) by Novartis Pharmaceuticals, and Otezla (apremilast) from Amgen.

The dynamics of the Psoriasis Vulgaris market are anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several Psoriasis Vulgaris pipeline therapies such as DMB-3115, Deucravacitinib, BAT2306, and others under investigation by key Psoriasis Vulgaris market players such as Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma, and many others.

Discover more about therapy set to grab substantial Psoriasis Vulgaris market share @ Psoriasis Vulgaris Treatment Market

Psoriasis Vulgaris Market Dynamics

DelveInsight’s analysts estimate that the Psoriasis Vulgaris market is poised to show significant growth in the coming years, mainly attributed to increasing cases, recent drug approvals, and the anticipated launch of novel therapies during the forecast period.

Psoriasis Vulgaris Market Driver

• Although topical agents help in providing symptomatic relief, they neither mitigate disease progression nor cure the disease. Hence, there is a need for more safe and efficacious therapies for localized Psoriasis Vulgaris treatment.
• Growing worldwide prevalence
• Ongoing research and development activities to identify novel and targeted therapies
• Increase in Awareness

Psoriasis Vulgaris Market Barrier

• Poor adherence and compliance with medications
• Entry of generics
• Challenging disease in terms of management
• Low awareness
• High economic burden

Know which therapy is expected to score the touchdown first @ Psoriasis Vulgaris Market Landscape and Forecast

Scope of the Psoriasis Vulgaris Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Psoriasis Vulgaris Companies: AbbVie, Sun Pharma, Johnson & Johnson, UCB, Inc., Valeant Pharmaceuticals, Eli Lilly and Company, Novartis Pharmaceuticals, Amgen, Meiji Seika Pharma, Soligenix, Dermavant Sciences, Lipidor AB, and many others.
• Key Psoriasis Vulgaris Pipeline Therapies: ME3183, SGX302, Tapinarof, AKP02/AKVANO, and several others.
• Psoriasis Vulgaris Therapeutic Assessment: Psoriasis Vulgaris current marketed and emerging therapies
• Psoriasis Vulgaris Dynamics: Psoriasis Vulgaris drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Psoriasis Vulgaris Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Psoriasis Vulgaris Market Overview at a Glance

4. Executive Summary of Psoriasis Vulgaris

5. Psoriasis Vulgaris Epidemiology and Market Methodology

6. Psoriasis Vulgaris: Disease Background and Overview

7. Diagnosis of Psoriasis Vulgaris

8. Psoriasis Vulgaris Treatment

9. Conclusion for Psoriasis Vulgaris

10. Psoriasis Vulgaris Epidemiology and Patient Population

11. Psoriasis Vulgaris Patient Journey

12. Key Endpoints in Psoriasis Vulgaris Clinical Trials

13. Psoriasis Vulgaris Marketed Therapies

14. Psoriasis Vulgaris Emerging Therapies

15. Psoriasis Vulgaris: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Psoriasis Vulgaris Market Drivers

19. Psoriasis Vulgaris Market Barriers

20. Psoriasis Vulgaris SWOT Analysis

21. Psoriasis Vulgaris Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Vulgaris Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

“Chronic Urticaria Treatment Market”

(Albany, USA) DelveInsight’s “Chronic Urticaria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic Urticaria, historical and forecasted epidemiology as well as the Chronic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Urticaria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Urticaria market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Urticaria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Urticaria market.

Request for a Free Sample Report @ Chronic Urticaria Market Forecast

Some facts of the Chronic Urticaria Market Report are:

• According to DelveInsight, Chronic Urticaria market size is expected to grow at a decent CAGR by 2032.
• Leading Chronic Urticaria companies working in the market are Sanofi-Aventis, Merck & Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, and others.
• Key Chronic Urticaria Therapies expected to launch in the market are Fexofenadin, Omalizumab, Desloratadine, Levocetirizine, Dupilumab, Rilzabrutinib, Remibrutinib, Benralizumab, Legelizumab, and many others.
• In March 2025, Novartis announced results of a 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines
• In February 2025, Celldex Therapeutics announced results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)
• In January 2025, Novartis announced results of a Real-world, Prospective, Multicenter Study of Safety and Effectiveness of Xolair® (Omalizumab) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Chinese Adolescents Inadequately Controlled With H1 Antihistamines
• In March 2025, Jiangsu Hansoh Pharmaceutical Co., Ltd. announced results of a Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
• In December 2024, Incyte Corporation announced results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
• In November 2024, Jasper Therapeutics, Inc announced results of a Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
• In May 2024, the culmination of a 52-week trial provided compelling evidence for the favourable safety profile of remibrutinib, a promising pharmaceutical compound. This extended study period is crucial, as it allows for a thorough assessment of a drug’s long-term tolerability.
• In February 2024, Sanofi’s experimental drug, rilzabrutinib, has shown promising results in a Phase II clinical trial for patients with chronic spontaneous urticaria, a condition marked by persistent hives and intense itching.

Chronic Urticaria Overview

Chronic Urticaria is a persistent skin disorder characterized by the recurrent appearance of itchy, raised, and swollen welts (hives) that last for more than six weeks. It can be classified into chronic spontaneous urticaria (CSU), which occurs without an identifiable trigger, and chronic inducible urticaria (CIndU), which is triggered by specific stimuli such as pressure, heat, cold, or sunlight. The condition is caused by the excessive release of histamine and other inflammatory mediators from mast cells and basophils, leading to itching, swelling, and discomfort.

The exact cause of Chronic Urticaria remains unclear, but it is often linked to autoimmune conditions, infections, allergic reactions, and stress. Diagnosis primarily involves clinical evaluation, patient history, and allergy testing, while treatment focuses on symptom management. Second-generation antihistamines like fexofenadine and desloratadine are the first-line treatment, while biologics such as omalizumab and emerging therapies like Bruton’s tyrosine kinase (BTK) inhibitors offer advanced options for refractory cases.

The increasing prevalence of allergic disorders and autoimmune diseases, along with advancements in targeted biologics and immunotherapies, is driving growth in the chronic urticaria treatment market. Research continues to focus on novel therapies to improve long-term symptom control and patient quality of life.

Learn more about Chronic Urticaria treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Chronic Urticaria Treatment Market

Chronic Urticaria Market

The Chronic Urticaria market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Urticaria market trends by analyzing the impact of current Chronic Urticaria therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic Urticaria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Urticaria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic Urticaria market in 7MM is expected to witness a major change in the study period 2019-2032.

Chronic Urticaria Epidemiology

The Chronic Urticaria epidemiology section provides insights into the historical and current Chronic Urticaria patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chronic Urticaria market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Chronic Urticaria Epidemiology @ Chronic Urticaria Prevalence

Chronic Urticaria Drugs Uptake

This section focuses on the uptake rate of the potential Chronic Urticaria drugs recently launched in the Chronic Urticaria market or expected to be launched in 2019-2032. The analysis covers the Chronic Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chronic Urticaria Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chronic Urticaria market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Urticaria Pipeline Development Activities

The Chronic Urticaria report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chronic Urticaria key players involved in developing targeted therapeutics.

Marketed Therapies in the Chronic Urticaria Market

Fexofenadine – Sanofi

Fexofenadine, sold under the brand name Allegra by Sanofi, is a second-generation antihistamine widely used for managing allergic conditions, including Chronic Urticaria (CU). It works by selectively blocking H1 histamine receptors, preventing histamine from triggering itching, swelling, and hives, which are hallmark symptoms of CU.

Desloratadine – Merck & Co

Desloratadine, a well-known second-generation antihistamine, is marketed under the brand name Clarinex by Merck & Co. It is commonly prescribed for Chronic Urticaria (CU) due to its proven efficacy in reducing persistent and distressing hives.

Xolair (omalizumab) – Roche/Novartis

Xolair (omalizumab), co-developed by Roche and Novartis, is a monoclonal antibody therapy that has revolutionized the treatment of Chronic Urticaria (CU), particularly for chronic spontaneous urticaria (CSU) cases that do not respond to standard treatments like antihistamines and corticosteroids.

Emerging Therapies in the Chronic Urticaria Market

Rilzabrutinib – Sanofi

Rilzabrutinib, an investigational therapy developed by Principia Biopharma (a subsidiary of Sanofi), is a promising candidate for Chronic Urticaria (CU) treatment. It is a Bruton’s tyrosine kinase (BTK) inhibitor, a drug class known for its role in modulating immune cell activity and reducing inflammatory responses.

Remibrutinib – Novartis

Remibrutinib, an investigational BTK inhibitor developed by Novartis, is being studied for its potential in treating Chronic Urticaria (CU), particularly chronic spontaneous urticaria (CSU). BTK is a crucial enzyme involved in the immune signaling pathways of mast cells, basophils, and B cells, which drive the inflammatory processes in urticaria.

Request for a sample report to understand more about the Chronic Urticaria pipeline development activities @ Chronic Urticaria Clinical Trials and Therapeutic Advancements

Chronic Urticaria Therapeutics Assessment

Major key companies are working proactively in the Chronic Urticaria Therapeutics market to develop novel therapies which will drive the Chronic Urticaria treatment markets in the upcoming years are Sanofi-Aventis, Merck & Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, and others.

Learn more about the emerging Chronic Urticaria therapies & key companies @ Hyperhidriosis Drugs Market

Chronic Urticaria Report Key Insights

1. Chronic Urticaria Patient Population

2. Chronic Urticaria Market Size and Trends

3. Key Cross Competition in the Chronic Urticaria Market

4. Chronic Urticaria Market Dynamics (Key Drivers and Barriers)

5. Chronic Urticaria Market Opportunities

6. Chronic Urticaria Therapeutic Approaches

7. Chronic Urticaria Pipeline Analysis

8. Chronic Urticaria Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chronic Urticaria Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Chronic Urticaria Competitive Intelligence Analysis

4. Chronic Urticaria Market Overview at a Glance

5. Chronic Urticaria Disease Background and Overview

6. Chronic Urticaria Patient Journey

7. Chronic Urticaria Epidemiology and Patient Population

8. Chronic Urticaria Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Urticaria Unmet Needs

10. Key Endpoints of Chronic Urticaria Treatment

11. Chronic Urticaria Marketed Products

12. Chronic Urticaria Emerging Therapies

13. Chronic Urticaria Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Urticaria Market Outlook (7 major markets)

16. Chronic Urticaria Access and Reimbursement Overview

17. KOL Views on the Chronic Urticaria Market

18. Chronic Urticaria Market Drivers

19. Chronic Urticaria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Urticaria Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight